Cargando…
NAIRscore as a biomarker for the quality of immune response to neoantigens is related with an increased overall survival in multiple myeloma
Neoantigen provides a promising breakthrough in tumor immunotherapy, although only a subset of patients responds well due to the quality of their immune response. However, few biomarkers have been reported to measure the quality of immune response to neoantigens and to predict prognosis of patients...
Autores principales: | Jian, Xingxing, Xu, Linfeng, Zhao, Jingjing, Wang, Yanhui, Zhou, Wen, Xie, Lu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9352810/ https://www.ncbi.nlm.nih.gov/pubmed/35950215 http://dx.doi.org/10.1016/j.omtn.2022.07.006 |
Ejemplares similares
-
Identification and Targeting of Mutant Neoantigens in Multiple Myeloma Treatment
por: Brancati, Valentina Urzì, et al.
Publicado: (2023) -
PGNneo: A Proteogenomics-Based Neoantigen Prediction Pipeline in Noncoding Regions
por: Tan, Xiaoxiu, et al.
Publicado: (2023) -
P852: NEOANTIGENS PREDICTED BY THE GNE NEOANTIGEN PIPELINE IN PATIENTS DIAGNOSED WITH DE NOVO MULTIPLE MYELOMA
por: Jiang, Y., et al.
Publicado: (2022) -
High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma
por: Miller, A, et al.
Publicado: (2017) -
Time-dependent endpoints as predictors of overall survival in multiple myeloma
por: Félix, Jorge, et al.
Publicado: (2013)